Skip to main content
. 2017 Jun 15;57(3):355–365. doi: 10.1007/s40262-017-0562-0

Fig. 1.

Fig. 1

Observed olaratumab serum concentrations in four completed studies. GBM glioblastoma multiforme, GIST gastrointestinal tumor, NSCLC nonsmall cell lung cancer, STS soft tissue sarcoma